Edwards Lifesciences shares rose 2.5% this morning to a price of $94.34. The stock is still trading within range of its average target price of $94.2, and over the last 52 weeks, it has recorded a -551.4% performance. Analysts have given the large-cap Specialty Industrial Machinery stock target prices ranging from $73.0 to $105.0 dollars per share, with an average rating of buy.
Edwards Lifesciences's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 1.8%. The stock's short ratio is 4.55. The company's insiders own 0.84% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 87.2%. In conclusion, we believe there is mixed market sentiment regarding Edwards Lifesciences.
Institutions Invested in Edwards Lifesciences
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Blackrock Inc. | 9% | 51,774,354 | $4,884,392,366 |
| 2023-03-31 | Vanguard Group, Inc. (The) | 9% | 51,750,835 | $4,882,173,584 |
| 2023-03-31 | State Street Corporation | 4% | 26,945,202 | $2,542,010,258 |
| 2023-03-31 | Capital International Investors | 4% | 25,759,106 | $2,430,113,965 |
| 2023-03-31 | Alliancebernstein L.p. | 3% | 20,445,472 | $1,928,825,753 |
| 2023-03-31 | Bank Of New York Mellon Corporation | 3% | 18,220,013 | $1,718,875,959 |
| 2023-03-31 | Wellington Management Group, LLP | 3% | 15,850,055 | $1,495,294,130 |
| 2023-03-31 | Brown Advisory Inc. | 2% | 14,088,366 | $1,329,096,396 |
| 2023-03-31 | Geode Capital Management, LLC | 2% | 12,214,619 | $1,152,327,111 |
| 2022-12-31 | Norges Bank Investment Management | 1% | 8,824,423 | $832,496,033 |
